## **Konstantinos Venetis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2473036/publications.pdf

Version: 2024-02-01

516710 610901 36 687 16 24 citations g-index h-index papers 36 36 36 421 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 2020, $11,719$ .	2.4	67
2	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Frontiers in Molecular Biosciences, 2022, 9, 834651.	3.5	63
3	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	4.1	53
4	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. Frontiers in Oncology, 2020, 10, 556718.	2.8	49
5	Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer, 2020, 150, 53-61.	2.0	36
6	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. Cells, 2021, 10, 1377.	4.1	35
7	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opinion on Investigational Drugs, 2022, 31, 593-605.	4.1	31
8	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treatment Reviews, 2020, 90, 102089.	7.7	27
9	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. Ecancermedicalscience, 2020, 14, 1150.	1.1	27
10	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell International, 2021, 21, 266.	4.1	26
11	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1461.	4.1	25
12	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	1.7	25
13	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. Critical Reviews in Oncology/Hematology, 2022, 172, 103643.	4.4	25
14	Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. Translational Cancer Research, 2020, 9, 4060-4064.	1.0	24
15	Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients' Quality of Life. Current Osteoporosis Reports, 2020, 18, 422-431.	3.6	20
16	Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 801-810.	1.7	19
17	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 829875.	2.8	19
18	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. Frontiers in Oncology, 2020, 10, 422.	2.8	17

#	Article	IF	CITATIONS
19	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. European Journal of Cancer, 2021, 145, 197-209.	2.8	16
20	Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study. Journal of Personalized Medicine, 2021, 11, 1369.	2.5	14
21	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histology and Histopathology, 2021, , 18376.	0.7	11
22	Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. Journal of Molecular Pathology, 2021, 2, 93-100.	1.2	10
23	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. BMC Cancer, 2021, 21, 1152.	2.6	9
24	Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients. Current Opinion in Pharmacology, 2021, 58, 27-34.	3.5	8
25	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Frontiers in Oncology, 2021, 11, 723693.	2.8	8
26	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. Gastrointestinal Disorders, 2020, 2, 341-352.	0.8	7
27	Metaplastic breast cancers and triple-negative breast cancers of no special type. European Journal of Cancer Prevention, 2021, Publish Ahead of Print, .	1.3	7
28	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Future Oncology, 2021, 17, 4607-4618.	2.4	4
29	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years' Single-Institution Experience of 762 Consecutive Patients. Cancers, 2022, 14, 1638.	3.7	3
30	Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Frontiers in Oncology, 2021, 11, 735476.	2.8	2
31	Abstract PS9-36: Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study. , 2021, , .		O
32	Abstract P4-07-02: Tumor microenvironment characteristics and prognosis in breast cancer during pregnancy: The role of differentially expressed immune-related genes. Cancer Research, 2022, 82, P4-07-02-P4-07-02.	0.9	0
33	Abstract P3-18-08: Feasibility and safety of breast-conserving surgery in early-stage breast cancers during the first trimester of pregnancy. Cancer Research, 2022, 82, P3-18-08-P3-18-08.	0.9	0
34	Abstract P4-10-15: Whole-body vibration combined with physical exercise to treat aromatase inhibitor-induced musculoskeletal symptoms in breast cancer women: Results of a pilot randomized controlled study. Cancer Research, 2022, 82, P4-10-15-P4-10-15.	0.9	0
35	Abstract P4-10-23: Combined analysis of PTEN and routinely assessed biomarkers reveals new high-risk subgroups of HR- or HER2+ breast cancers. Cancer Research, 2022, 82, P4-10-23-P4-10-23.	0.9	0
36	Hereditary gastric and breast cancer syndromes with lung metastasis: narrative review of molecular and clinical insights. AME Surgical Journal, 0, .	0.0	0